311
Participants
Start Date
October 31, 2011
Primary Completion Date
January 31, 2013
Study Completion Date
August 31, 2013
dapagliflozin
10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
placebo
matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
Research Site, Edmonton
Research Site, Winnipeg
Research Site, St. John's
Research Site, Halifax
Research Site, Sydney Mines
Research Site, Brampton
Research Site, Etobicoke
Research Site, Markham
Research Site, Smiths Falls
Research Site, Kensington
Research Site, Laval
Research Site, Québec
Research Site, Beroun
Research Site, České Budějovice
Research Site, Jílové u Prahy
Research Site, Prague
Research Site, Semily
Research Site, Vyškov
Research Site, Aßlar
Research Site, Berlin
Research Site, Dresden
Research Site, Falkensee
Research Site, Neuwied
Research Site, Pirna
Research Site, Kielce
Research Site, Lodz
Research Site, Lublin
Research Site, Poznan
Research Site, Warsaw
Research Site, Zgierz
Research Site, Banská Bystrica
Research Site, Košice
Research Site, Považská Bystrica
Research Site, Rimavská Sobota
Research Site, Barcelona
Research Site, Santa Coloma de Gramanet (bcn)
Research Site, A Coruña
Research Site, Oviedo
Research Site, A Coruña
Research Site, Barcelona
Research Site, Oviedo
Research Site, Santa Coloma de Gramenet (bcn)
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
AstraZeneca
INDUSTRY